Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ComboMATCH Trial of Selumetinib and Olaparib or Selumetinib Alone in RAS Pathway Mutant Ovarian and Endometrial Cancers
NCT05554328Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of olaparib in ovarian cancer, endometrial cancer (EC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Apr 2023; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerendometrial cancer (EC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05554328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554328.